Using biomarkers to predict progression from clinically isolated syndrome to multiple sclerosis

Table 1 Demographic characteristics of the different subject populations

	#	Age	P*	Gender	P	Ethnicity	P
	#	Age	P*	(% F)	P	(%, C/AA/As/H)**	P
MS	199	43 ± 10	NS	76	NS	80/20/0/0	NS
OND-I	84	46 ± 10	NS	68	NS	67/33/0/0	NS
OND-NI	119	46 ± 10	NS	67	NS	68/26/3/1	NS
CTRL	114	41 ± 11		77		71/22/3/3
CIS ➔MS	46	35 ± 6	NS	72	NS	82/14/4/0	NS

MS MS-treatment naïve (N = 85), MS with established disease on medications (N = 114), OND-I other inflammatory neurologic disorders, acute disseminated encephalomyelitis (N = 4), Bell’s Palsy (N = 3), CNS lupus (N = 2), Guillaine Barre (N = 4), Myasthenia Gravis (N = 3), Neuromyelitis optica (N = 26), Optic neuritis (N = 1), Transverse myelitis (N = 41), OND-NI other non-inflammatory neurologic disorders, Alzheimer’s (N = 6), cerebral ataxia (N = 2), cerebral bleed (N = 2), cervical radiculopathy (N = 6), drug-induced movement disorder (N = 1), dystonia (N = 1), epilepsy (N = 4), essential tremor (N = 9), Huntington’s disease (N = 1), hydrocephalus (N = 1), median neuropathy (N = 2), meningioma (N = 1), migraine (N = 30), Parkinsons (N = 23), peripheral neuropathy (N = 1), pseudotumor (N = 3), restless leg syndrome (N = 6), seizures (N = 9), stroke (N = 10), CIS ➔ MS subjects who had clinically isolated syndrome at the time of the blood draw who have developed clinically definite MS.
U.S sites: TN, MA, MD, NY, SC, AZ, TX, CA, samples from sites in MS, MD, NY, AZ, and CA were obtained through the Accelerated Cure Project, European sites: Denmark, Netherlands
*P calculated by Student’s T-test [18] or Fisher’s exact test, NS: P > 0.05, calculated relative to CTRL.
**C Caucasian, AA African American, As Asian, H Hispanic.